Evidently, the pro-oncogenic activity of TLR4 on the MM cells is counteracted by FDC-SPARC upon TLR4 stimulation, and the outcome of this MM/stromal balance partly contributes to the severity and progression of the disease. The gene discussed is TLR4; the disease is Miyoshi myopathy.